Who is sponsoring NCT05681026?

NCT05681026 is sponsored by M.D. Anderson Cancer Center.

What drugs are being tested in NCT05681026?

Interventions in NCT05681026: Yoga Sessions, Questionnaries, Interviews.

What condition does NCT05681026 study?

NCT05681026 studies Hematopoietic Stem Cell Transplantation, Cancer.

Is NCT05681026 still recruiting?

NCT05681026 is currently recruiting now. Last updated 27 February 2026.

Last reviewed 2026-02-27 · How we verify

NCT05681026

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Cultural Tailoring and Pilot Testing of an Inpatient Yoga Therapy Program for Cancer Patients Undergoing Hematopoietic Stem Cell Transplantation in India, Tanzania, and the United States

Recruiting now NA Last updated 27 February 2026

What this trial tests

NA trial testing Yoga Sessions in Hematopoietic Stem Cell Transplantation in 60 participants. Currently enrolling.

Timeline

28 August 2023

Primary endpoint
31 January 2028

31 January 2028

Quick facts

Lead sponsor	M.D. Anderson Cancer Center
Phase	NA
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	supportive care
Enrollment	60
Start date	28 August 2023
Primary completion	31 January 2028
Estimated completion	31 January 2028
Sites	3 locations across United States, Tanzania, India

Drugs / interventions tested

Yoga Sessions
Questionnaries
Interviews

Conditions studied

Hematopoietic Stem Cell Transplantation — all drugs for Hematopoietic Stem Cell Transplantation →
Cancer — all drugs for Cancer →

Sponsor

M.D. Anderson Cancer Center — full company profile →

Who can join

18 and older, any sex, with Hematopoietic Stem Cell Transplantation or Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To develop and measure the effects of a culturally sensitive yoga program for inpatients

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Cultural Adaptation and Feasibility of an Inpatient Yoga Intervention for Patients Undergoing Hematopoietic Stem Cell Transplantation in Tanzania, India, and the United States: A Study Protocol.
Mallaiah S, Olson AL, Daher M, Mama SK, et al · · 2026 · PMID 41938074 · DOI 10.1177/27536130261440941
Adapting Yoga Therapy to Meet the Needs of Inpatients Undergoing Hematopoietic Stem Cell Transplantation: Insights From an International, Multisite, Qualitative Study.
Mallaiah S, Majumdar V, Mama SK, Olson AL, et al · · 2026 · PMID 41791008 · DOI 10.1200/go-25-00567

Verify or expand the search:

Other recruiting trials for Hematopoietic Stem Cell Transplantation

Currently open trials in the same condition.

NCT07400328 — Amimestrocel Injection for Preventing Severe Oral Mucositis in HSCT Patients · Phase 2 · recruiting
NCT07349498 — Cardiovascular Outcomes and Risk Evaluation Among Recipients of Hematopoietic Stem Cell Transplantation · recruiting
NCT07442513 — Comparison of Etamsylate Versus Placebo to Prevent Bleeding in HSCT · Phase 3 · recruiting
NCT06904053 — Metagenomics Next-generation Sequencing Approach to Detect Microbial DNA/RNA Overtime in Individuals Undergoing Hematopo · recruiting
NCT06708507 — Tissue-resident Immune Cell Subsets in aGVHD · recruiting

Other M.D. Anderson Cancer Center trials

Trials by the same sponsor.

NCT07053020 — A Phase 1b/2 Open-label, Dose-ranging Safety and Efficacy Study of Oral Cladribine in Patients With Acute Myeloid Leukem · Phase 1, PHASE2 · not yet recruiting
NCT07052994 — A Phase Ia/Ib Trial of Revumenib Combined With Cytarabine, Daunorubicin, and Gemtuzumab Ozogamicin (GO) in Frontline and · Phase 1 · not yet recruiting
NCT07137481 — Phase II Study of CD5 CAR Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Che · Phase 2 · not yet recruiting
NCT07162480 — Phase II Trial of Puxitatug Samrotecan (AZD8205) in Advanced, Recurrent or Metastatic (R/M) Aggressive Adenoid Cystic Ca · Phase 2 · not yet recruiting
NCT07076498 — Engineered HSV-1 M032 for the Treatment of Children and Adults With Newly Diagnosed Diffuse Midline Glioma After Standar · Phase 1 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05681026 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by M.D. Anderson Cancer Center
Last refreshed: 27 February 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05681026.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing